Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Le Tourneau

Showing results (11-20 of 234) with videos related to

Pageof 24
Sort By:
La Revue Du Praticien|June 23, 2021
["Immunotherapy in head and neck squamous cell carcinoma"]Grégoire Marret, Édith Borcoman, Christophe Le Tourneau
Expert Opinion on Biological Therapy|July 20, 2019
Pembrolizumab for the treatment of cervical cancerGrégoire Marret, Edith Borcoman, Christophe Le Tourneau
Therapeutics and Clinical Risk Management|March 25, 2008
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)Christophe Le Tourneau, Eric Raymond, Sandrine Faivre
Current Opinion in Oncology|July 2, 2019
Molecular screening programs in different countries: what we learned and perspectivesEdith Borcoman, Christophe Le Tourneau, Maud Kamal
International Journal of Molecular Sciences|June 2, 2019
Hyperprogression under ImmunotherapyMaxime Frelaut, Christophe Le Tourneau, Edith Borcoman
Current Opinion in Oncology|March 7, 2022
Nanoparticle therapy for head and neck cancersCaroline Hoffmann, Colette Shen, Christophe Le Tourneau
Bulletin Du Cancer|June 3, 2014
[Recurrence of upper aerodigestive tract tumors]Laurent Martin, Mustapha Zoubir, Christophe Le Tourneau
Current Opinion in Oncology|March 26, 2023
Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinomaGrégoire Marret, Edith Borcoman, Christophe Le Tourneau
JCO Precision Oncology|January 7, 2022
Insights for Quantifying the Long-Term Benefit of Immunotherapy Using Quantile RegressionBassirou Mboup, Christophe Le Tourneau, Aurélien Latouche
Cancers|June 2, 2021
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaEdith Borcoman, Gregoire Marret, Christophe Le Tourneau
Pageof 24

Showing results (11-20 of 234) with videos related to

Sort By:
Pageof 24
La Revue Du Praticien|June 23, 2021
["Immunotherapy in head and neck squamous cell carcinoma"]Grégoire Marret, Édith Borcoman, Christophe Le Tourneau
Expert Opinion on Biological Therapy|July 20, 2019
Pembrolizumab for the treatment of cervical cancerGrégoire Marret, Edith Borcoman, Christophe Le Tourneau
Therapeutics and Clinical Risk Management|March 25, 2008
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)Christophe Le Tourneau, Eric Raymond, Sandrine Faivre
Current Opinion in Oncology|July 2, 2019
Molecular screening programs in different countries: what we learned and perspectivesEdith Borcoman, Christophe Le Tourneau, Maud Kamal
International Journal of Molecular Sciences|June 2, 2019
Hyperprogression under ImmunotherapyMaxime Frelaut, Christophe Le Tourneau, Edith Borcoman
Current Opinion in Oncology|March 7, 2022
Nanoparticle therapy for head and neck cancersCaroline Hoffmann, Colette Shen, Christophe Le Tourneau
Bulletin Du Cancer|June 3, 2014
[Recurrence of upper aerodigestive tract tumors]Laurent Martin, Mustapha Zoubir, Christophe Le Tourneau
Current Opinion in Oncology|March 26, 2023
Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinomaGrégoire Marret, Edith Borcoman, Christophe Le Tourneau
JCO Precision Oncology|January 7, 2022
Insights for Quantifying the Long-Term Benefit of Immunotherapy Using Quantile RegressionBassirou Mboup, Christophe Le Tourneau, Aurélien Latouche
Cancers|June 2, 2021
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaEdith Borcoman, Gregoire Marret, Christophe Le Tourneau
Pageof 24